|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:phenytoin
|
|
gptkbp:approvalYear
|
1953
|
|
gptkbp:ATCCode
|
gptkb:N03AB02
|
|
gptkbp:CASNumber
|
57-41-0
|
|
gptkbp:chemicalFormula
|
C15H12N2O2
|
|
gptkbp:contraindication
|
hypersensitivity to phenytoin
|
|
gptkbp:discoveredBy
|
gptkb:Heinrich_Biltz
|
|
gptkbp:discoveredIn
|
1908
|
|
gptkbp:drugClass
|
anticonvulsant
|
|
gptkbp:eliminationHalfLife
|
22 hours
|
|
gptkbp:form
|
gptkb:tablet
capsule
injection
oral suspension
|
|
gptkbp:genericName
|
gptkb:phenytoin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dilantin
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:isoniazid
gptkb:warfarin
gptkb:carbamazepine
cimetidine
oral contraceptives
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
sodium channel blocker
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
liver function
renal function
blood levels
|
|
gptkbp:notEffectiveAgainst
|
absence seizures
|
|
gptkbp:overdoseSymptoms
|
coma
loss of coordination
slurred speech
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:prescribes
|
tonic-clonic seizures
partial seizures
|
|
gptkbp:riskOfStevensJohnsonSyndrome
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
nystagmus
rash
drowsiness
ataxia
gingival hyperplasia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:usedFor
|
epilepsy
seizure disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:phenytoin
gptkb:Rhône-Poulenc_Rorer
|
|
gptkbp:bfsLayer
|
6
|